Wednesday, November 28, 2018 6:23:36 PM
HR2, wouldn't you think getting past the FDA hurdle isn't as difficult given that the trial has, for the most part, ended or in its final stages. It just seems strange to fight this hard for a decade and get a step from the finish-line only to give it to someone else to step over.
And in regards to the interests at large, once NWBO establishes efficacy from the FDA or a BP partnership, those interest, IMHO, will have been neutralized. If NWBO has damn near a cure for cancer and have the patents for it along with 12 years of data (i.e. a barrier to the market), what can those interest do?
Even the difficult aspects of commercialization has been minimized (in that 80+ hospitals have already been trained on the process) with the exception of the scale-up of manufacturing.
IMHO, NWBO did a lot of heavy lifting to get to this point. From here to commercialization, relatively speaking, would appear to be significantly less difficult mainly because once efficacy is undeniable funding is available. When you have $$$ to do what you have to do, the doing ain't so hard.
But, I haven't run a business and am talking about something over my head.
And in regards to the interests at large, once NWBO establishes efficacy from the FDA or a BP partnership, those interest, IMHO, will have been neutralized. If NWBO has damn near a cure for cancer and have the patents for it along with 12 years of data (i.e. a barrier to the market), what can those interest do?
Even the difficult aspects of commercialization has been minimized (in that 80+ hospitals have already been trained on the process) with the exception of the scale-up of manufacturing.
IMHO, NWBO did a lot of heavy lifting to get to this point. From here to commercialization, relatively speaking, would appear to be significantly less difficult mainly because once efficacy is undeniable funding is available. When you have $$$ to do what you have to do, the doing ain't so hard.
But, I haven't run a business and am talking about something over my head.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
